Melanotan I (Afamelanotide) – Effects and Uses
Melanotan I (afamelanotide) is a synthetic peptide that stimulates skin pigmentation and is medically approved for certain light-sensitivity disorders.
Wissenswertes über "Melanotan I"
Melanotan I (afamelanotide) is a synthetic peptide that stimulates skin pigmentation and is medically approved for certain light-sensitivity disorders.
What is Melanotan I?
Melanotan I, scientifically known as afamelanotide, is a synthetically produced analogue of the naturally occurring hormone alpha-melanocyte-stimulating hormone (alpha-MSH). It acts on the melanocytes of the skin – the pigment-producing cells – and promotes the synthesis of melanin, the brown skin pigment. Melanotan I was originally developed at the University of Arizona as part of research into skin cancer prevention strategies.
Mechanism of Action
Melanotan I binds selectively to the melanocortin-1 receptor (MC1R), which is primarily expressed on the surface of melanocytes. This binding triggers an intracellular signalling cascade that leads to increased production of eumelanin – the dark brown to black form of melanin – which provides a natural degree of UV protection for the skin. Compared to the related compound Melanotan II, Melanotan I acts much more selectively and shows minimal activity at other melanocortin receptors, resulting in a more favourable side effect profile.
Medical Use
Marketed under the brand name Scenesse, afamelanotide has received regulatory approval in the European Union and other countries for the treatment of erythropoietic protoporphyria (EPP). EPP is a rare, genetically inherited metabolic disorder in which patients experience severe pain and skin symptoms upon exposure to light. By increasing melanin production, the drug provides a degree of photoprotection that reduces symptoms and significantly improves the quality of life of affected patients.
Approved Indication
- Erythropoietic Protoporphyria (EPP): Prevention of phototoxicity in adults
Non-Approved Uses (Off-Label)
Outside of a medical context, Melanotan I is used by some individuals to enhance skin tanning. This use is not approved, not regulated, and is associated with significant health risks. In many countries, purchasing and using such products outside of a regulated medical framework is illegal.
Administration and Dosage
Melanotan I (afamelanotide) is administered as a subcutaneous implant, inserted under the skin by a healthcare professional. The implant releases the active substance slowly over approximately 60 days. Implantation typically takes place prior to the sun season or before an anticipated increase in light exposure. The dosage and frequency of implantation are determined individually by the treating physician.
Side Effects
Melanotan I is considered to be relatively well tolerated compared to Melanotan II. However, the following side effects may occur:
- Nausea (especially following implantation)
- Erythema or reactions at the implantation site
- Flushing
- Fatigue
- Spontaneous erections (rare, due to lower MC4R activity compared to Melanotan II)
- Changes in existing moles (naevi)
Patients should have their skin regularly monitored for changes in moles or new pigmentation and should inform their doctor of any concerns.
Safety and Regulatory Status
As Scenesse (afamelanotide), Melanotan I is an approved medicinal product subject to strict medical supervision. Unregulated forms available via the internet or grey market may be contaminated, incorrectly dosed, or counterfeit, and pose a significant health risk. The use of such products is strongly discouraged.
Distinction from Melanotan II
Melanotan I and Melanotan II are related but distinct peptides. Melanotan II binds to multiple melanocortin receptors (MC1R, MC3R, MC4R, MC5R) and therefore has a broader side effect profile, including sexual arousal and more pronounced gastrointestinal effects. Melanotan I is considerably more selective and has received formal medical approval as a result.
References
- European Medicines Agency (EMA): Scenesse (Afamelanotide) – Product Information and Assessment Report, 2014. Available at: www.ema.europa.eu
- Harms J. et al.: Afamelanotide for Erythropoietic Protoporphyria – New England Journal of Medicine, 2015; 373:48–59.
- Langendonk J.G. et al.: Afamelanotide for Erythropoietic Protoporphyria – Journal of Hepatology, 2012. doi:10.1016/j.jhep.2012.03.035
Best-selling products
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, probiotic lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryTerminology
Involuntary Commitment Law
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: Melanotan I + Melanotan 1 + MT-I + MT1 + Afamelanotide